Skip to main content
. 2005 Mar 8;5:27. doi: 10.1186/1471-2407-5-27

Table 4.

Multivariate model of factors associated with undergoing aggressivea treatment for clinically localized cancer (n = 2796).

Variable Received aggressive treatment Wald F P-value
Adjusted percentages (95% CI) Odds ratio (95% CI)

Screening history 0.05
 Not-screened 76 (74, 78) 1.0
 Screened 70 (64, 76) 1.5 (1.1 – 2.3)
SEER registry < 0.01
 Los Angeles 71 (67, 75) 1.0
 Atlanta 89 (85, 93) 4.8 (2.7 – 8.5)
 Connecticut 77 (73, 81) 1.5 (1.1 – 2.2)
 New Mexico 72 (66, 78) 1.1 (0.7 – 1.7)
 Seattle 73 (67, 79) 1.2 (0.8 – 1.8)
 Utah 77 (73, 81) 1.5 (1.0 – 2.3)
Ethnicity < 0.01
 Non-Hispanic white 76 (74, 78) 1.0
 Non-Hispanic black 69 (63, 75) 0.6 (0.4 – 0.9)
 Hispanic 79 (75, 83) 1.2 (0.8 – 1.9)
Age < 0.01
 < 49 95 (92, 100) 1.0
 50–64 89 (87, 91) 0.4 (0.2 – 1.2)
 65–74 79 (77, 81) 0.2 (0.1 – 0.5)
 75+ 41 (35, 47) 0.03 (0.01 – 0.08)
Current marital status < 0.01
 Married 77 (75, 79) 1.0
 Unmarried 71 (67, 75) 0.6 (0.5 – 0.8)
Education 0.95
 < High school degree 76 (72, 80) 1.0
 High school/college 76 (74, 78) 1.0 (0.7 – 1.3)
 College degree 76 (72, 80) 0.9 (0.7 – 1.4)
Insurance 0.25
 Private 76 (74, 78) 1.0
 Medicare/Public 74 (68, 80) 0.9 (0.6 – 1.4)
 Unknown 81 (75, 87) 1.6 (0.9 – 2.8)
Income (annual) 0.98
 < $20,000 76 (72, 80) 1.0
 $20 – 40,000 76 (72, 80) 1.0 (0.7 – 1.4)
 $40,000 + 76 (72, 80) 1.0 (0.7 – 1.5)
Comorbid conditions 0.01
 None 78 (74, 82) 1.0
 1 77 (73, 81) 0.9 (0.7 – 1.2)
 2 77 (73, 81) 0.9 (0.6 – 1.3)
 3+ 68 (62, 74) 0.5 (0.3 – 0.7)
Health status < 0.01
 Excellent 80 (76, 84) 1.0
 Good 77 (75, 79) 0.8 (0.5 – 1.2)
 Fair or poor 67 (61, 73) 0.4 (0.3 – 0.7)
PSA (ng/ml) < 0.01
 <4 69 (63, 75) 1.0
 ≥ 4 77 (75, 79) 1.7 (1.1 – 2.6)
 Unknown 68 (60, 76) 0.9 (0.5 – 1.9)
Gleason score < 0.01
 2 – 4 68 (62, 74) 1.0
 5 – 7 78 (76, 80) 2.0 (1.4 – 2.8)
 8 – 10 71 (65, 77) 1.2 (0.7 – 2.0)
 Unknown 80 (74, 86) 2.3 (1.3 – 4.2)

aAggressive treatment was defined as radical prostatectomy or radiation therapy.

Legend: SEER = Surveillance, Epidemiology, and End Results; PSA = prostate-specific antigen